ImageneBio (IMA) Price & Analysis

Compare

109 Followers

IMA Stock Chart & Stats

$7.01

Market closed

$7.01

Day’s Range― - ―

52-Week Range$5.70 - $19.20

Previous CloseN/A

VolumeN/A

Average Volume (3M)69.52K

Market Cap

$82.22M

Enterprise Value-$12.71M

Total Cash (Recent Filing)$142.58M

Total Debt (Recent Filing)$10.96M

Price to Earnings (P/E)―

Beta0.67

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding11,181,672

10 Day Avg. Volume58,561

30 Day Avg. Volume69,515

Financial Highlights & Ratios

PEG Ratio0.69

Price to Book (P/B)7.54

Price to Sales (P/S)271.35

P/FCF Ratio-20.64

Enterprise Value/Market Cap-0.15

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.52

Enterprise Value/Ebitda0.23

Forecast

1Y Price Target

$2.00

Price Target Upside-71.47% Downside

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development StrategyAdding dose‑ranging and loading‑dose cohorts in the Phase IIb study improves the chance of identifying an effective regimen and lowers the risk of inconclusive results.

FinancingCompleted $75 million private financing after the reverse merger provides funding to support ongoing clinical activities and reduces immediate fundraising pressure.

Safety DifferentiationA non‑T‑cell–depleting design targeting OX40 could deliver a safer profile while preserving efficacy, offering a potential differentiator versus other immune therapies.

Bears Say

Capital And Dilution RiskHigh development costs combined with a constrained cash position may necessitate sizable equity raises, increasing dilution risk for current investors.

Competitive Pressure And Limited Monotherapy ProspectsCompetitors showing stronger efficacy and safety, particularly with anti‑OX40L approaches, limit monotherapy market opportunity for IMG‑007 and heighten commercialization challenges.

Single-asset ConcentrationReliance on a single clinical‑stage candidate concentrates company risk, so an adverse trial outcome could materially harm shareholder value.

ImageneBio News

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/6/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 1.40% in...

8h ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/4/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.28% in...

2d ago

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/3/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.22% in...

4d ago

CLB

Vanguard Total Stock Market ETF (VTI) Daily Update—2/2/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down by 0.31%...

4d ago

CLB

Vanguard VTI Daily Snapshot — Jan. 30

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down by 0.30%...

7d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Update—1/29/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up by 0.15%...

8d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Update—1/28/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up by 0.27%...

9d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/27/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up by 0.30%...

10d ago

CLB

VTI ETF Sees $1B Inflows — Are Investors Turning More Bullish?

The Vanguard Total Stock Market ETF ($VTI) tracks the broader U.S. stock market. The ETF saw strong investor...

12d ago

CLB

ImageneBio Chief Medical Officer Resigns, Transition Planned

ImageneBio ( ($IMA) ) just unveiled an update. On December 12, 2025, ImageneBio announced that its Chief Medical...

2M ago

IMA

ImageneBio assumed at Underperform from Neutral at Wedbush

Wedbush analyst Martin Fan downgraded ImageneBio (IMA) to Underperform from Neutral with a price target of $2, down...

2M ago

IMA

ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year

Reports Q3 revenue $0 vs. $3.5M last year. “We are in a wonderful position as we complete our...

3M ago

IMA

ImageneBio initiated with an Outperform at Leerink

Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares...

4M ago

IMA

SNY

ImageneBio files to sell 2.51M shares of common stock for holders

16:21 EDT ImageneBio (IMA) files to sell 2.51M shares of common stock for holders Published first on TheFly...

5M ago

IMA

IMA FAQ

What was ImageneBio’s price range in the past 12 months?

ImageneBio lowest stock price was $5.70 and its highest was $19.20 in the past 12 months.

What is ImageneBio’s market cap?

ImageneBio’s market cap is $82.22M.

When is ImageneBio’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were ImageneBio’s earnings last quarter?

ImageneBio released its earnings results on Aug 07, 2025. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.358.

Is ImageneBio overvalued?

According to Wall Street analysts ImageneBio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ImageneBio pay dividends?

ImageneBio does not currently pay dividends.

What is ImageneBio’s EPS estimate?

ImageneBio’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ImageneBio have?

ImageneBio has 11,181,672 shares outstanding.

What happened to ImageneBio’s price movement after its last earnings report?

ImageneBio reported an EPS of -$0.688 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -0.697%.

Which hedge fund is a major shareholder of ImageneBio?

Currently, no hedge funds are holding shares in IMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ImageneBio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-33.05%

Trailing 12-Months

Asset Growth

-19.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ImageneBio

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

ImageneBio (IMA) Earnings & Revenues

Historic Earnings Reports

IMA Stock 12 Month Forecast

Average Price Target

$2.00

▼(-71.47% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.09,6.6984615384615385,6.306923076923077,5.915384615384616,5.523846153846154,5.132307692307693,4.740769230769231,4.349230769230769,3.957692307692308,3.5661538461538465,3.174615384615385,2.7830769230769237,2.3915384615384614,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.09,6.6984615384615385,6.306923076923077,5.915384615384616,5.523846153846154,5.132307692307693,4.740769230769231,4.349230769230769,3.957692307692308,3.5661538461538465,3.174615384615385,2.7830769230769237,2.3915384615384614,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.09,6.6984615384615385,6.306923076923077,5.915384615384616,5.523846153846154,5.132307692307693,4.740769230769231,4.349230769230769,3.957692307692308,3.5661538461538465,3.174615384615385,2.7830769230769237,2.3915384615384614,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.52,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.51,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.09,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >